Background No studies have reported any survival benefit in recurrent MPM. We examined
the effect of nivolumab, in patients who presented with progressive disease and agreed to …

Objectives Second-line immune checkpoint inhibition (ICI) was recently shown to have a
survival advantage over placebo in malignant pleural mesothelioma (MPM), but the survival …

TPS8581 Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer with
a 5-year overall survival (OS) rate of< 10%. At diagnosis, most patients (pts) have …

Background In CheckMate 743 (NCT02899299), a phase III randomized trial, NIVO+ IPI
provided statistically significant and clinically meaningful improvement in overall survival vs …

Abstract On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line
treatment for adult patients with unresectable malignant pleural mesothelioma (MPM). The …

8565 Background: We conducted a phase II trial (NCT02399371) of P in previously treated
MM to characterize activity in a non-selected population and determine a PD-L1 expression …

Introduction: Platinum-based chemotherapy is the current first-line standard therapy for
unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint …

Introduction Unresectable pleural mesothelioma is a poor prognosis disease. Improvement
in overall survival (OS) has been shown with PEMETREXED combined with CISPLATIN …

Background The phase IIR trial IFCT-1501 (MAPS2) tested nivo or nivo+ ipi in pts with
relapsed MPM as second/third-line. This trial reached its primary endpoint with 40% or more …

LBA8505 Background: The vast majority of pts with PM have unresectable disease, due to
co-morbidities and/or advanced stage. In unresectable PM, standard first line treatment has …